Clinical Research Details
Title:
Phase II study of Carboplatin, Nanoparticle Albumin-bound Paclitaxel (ABI-007) and Bevacizumab (Avastin) as the first line therapy in metastatic breast cancer.
Purpose:
The purpose of this study is to determine the progression free survival of this regimen in the first line metastatic breast cancer setting.
Study Number:
200027
Number of Patients:
72
Elgibility:
Participants must have histologically confirmed breast cancer that has recurred or metastasized. Participants must have not have received prior chemotherapy for metastatic disease.
Treatment:
All participants will be given carboplatin and bevacizumab every 21 days with weekly albumin-bound paclitaxel.
Principal Investigator:
Enrollment Phone:
(708) 327-3222